Early infection and progression of cystic fibrosis lung disease.
about
ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expressionProteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patientsAssociation between spirometry controlled chest CT scores using computer-animated biofeedback and clinical markers of lung disease in children with cystic fibrosisRecent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosisPseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.Clinical significance of microbial infection and adaptation in cystic fibrosis.Evidence-based medicine in cystic fibrosis: how should practice change?Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosaCystic fibrosis lung environment and Pseudomonas aeruginosa infection.A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic FibrosisPseudomonas aeruginosa ExoT Induces Mitochondrial Apoptosis in Target Host Cells in a Manner That Depends on Its GTPase-activating Protein (GAP) Domain Activity.Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens.Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.Phenotypic characterization and PCR-Ribotypic profile of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Iran.Intensive care management of the patient with cystic fibrosis.Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosisNew insights into the pathogenesis of cystic fibrosis sinusitisManagement of the upper airway in cystic fibrosis.Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis.Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.The role of bacterial biofilms in chronic infections.Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection.Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa.A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis.Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis.Dornase alfa in early cystic fibrosis lung disease.Detecting early structural lung damage in cystic fibrosis.Nitrosative stress inhibits production of the virulence factor alginate in mucoidPseudomonas aeruginosaPeripheral Protein Quality Control as a Novel Drug Target for CFTR StabilizerLife in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosaMucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients
P2860
Q28493038-5D33C505-9446-4FB0-AEF8-924474248EFBQ33474273-4E57F6A8-E0F7-4138-9D4E-FB407F6D4B92Q33715997-29FC0C24-6CB1-4DCA-9912-BB1CEA315FF3Q33810871-9DDFBC3F-5710-43D0-AADD-9ADE9303FF39Q33862073-12F8F08E-7DAC-4207-A749-DADB0C6FF744Q34106186-96F41E9D-38C8-4808-86A5-FC715E428E19Q34180770-F8090253-17BE-4D7D-9DB0-425449588D2AQ34491552-C3DAB0D8-074A-4C4D-8116-56FB5C0C08CBQ34804108-7C0F18D7-D864-484D-9600-C2040A0BE258Q35127240-D41D9E3E-7181-4628-9F1A-4D3182989CD5Q35800789-1F3422D0-2304-46B5-9F78-9EFEDC96451BQ36213685-661AA96B-6712-4DE2-9B82-2CCB69BEF4AEQ36234916-6A5F9661-BD05-483A-96F2-44D5C62C4954Q36323536-2D934E3F-CF16-4F7C-911F-216AA8C52B90Q36732549-FBF9D00E-7DC9-4A9F-8DF0-49D7CC0B6B79Q36999096-4573A7CD-9FBD-4404-B3C7-D42DBB863C4DQ37068359-A8D394BC-DF7D-4973-BADC-5EC519F7EECEQ37149666-8DD7220B-3613-4D8B-947D-3137B3F9A162Q37366880-21CC92CF-1183-4015-92B2-79A2F4190E6DQ37624582-866CFC13-C278-4F19-8C29-352EEEBEEA65Q38253805-11325477-C170-4A28-A0E3-13ABA9A41022Q38358624-4633CDAE-763C-4E5A-BB80-50E6E4A17303Q39218303-948493FA-0661-40A0-A8B7-26D7F9325808Q39426830-E45943C8-623A-4FC3-BE7E-251A39F36EF0Q39997040-445AE440-C1FF-4456-B1AB-DC440CA2CECEQ40518496-B08790A1-11BB-42FA-A95C-51F4A3BED54CQ43121719-023F4DEA-D712-4CE4-9422-39FA9DA993B8Q43121813-B61DC235-E63B-4448-BC9C-36DC7496BC89Q47692118-0B35EB3B-FE17-4359-B85A-FC70E0352DB3Q49490627-178938EA-115A-4416-8FF3-A2C6E0E0E689Q51705669-4074258D-0070-426E-B40B-2DAA3237BF7EQ51705672-80071C7F-6161-487C-86E3-4C6FB42C0674Q57036685-E4953142-8219-4BAB-9BA3-B14EC43DC857Q57490973-2D5E1262-DEED-4772-AA95-1D29F2667F09Q58715300-81C738FB-46C8-4D25-BE1A-368819FDFF71Q59139095-B691CA4F-DFE7-4FD0-97C9-81E8D48E7C6A
P2860
Early infection and progression of cystic fibrosis lung disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Early infection and progression of cystic fibrosis lung disease.
@en
type
label
Early infection and progression of cystic fibrosis lung disease.
@en
prefLabel
Early infection and progression of cystic fibrosis lung disease.
@en
P2860
P356
P1476
Early infection and progression of cystic fibrosis lung disease.
@en
P2093
Christian Koch
P2860
P304
P356
10.1002/PPUL.10135
P577
2002-09-01T00:00:00Z